(EDIT) Editas Medicine, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(EDIT) Editas Medicine, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Editas Medicine, Inc. BCG Matrix gives a structured view of the company’s portfolio, helping you see which products or business units may be Stars, Cash Cows, Question Marks, or Dogs. The page already shows a real preview of the actual analysis, so you can review the format and content before purchasing. Buy the full version to get the complete ready-to-use report.
Stars
EDIT-301 SCD/TDT Phase 1/2
EDIT-301 is Editas Medicine, Inc.’s lead hematology program for sickle cell disease and transfusion-dependent beta-thalassemia, both large unmet-need markets with strong gene-editing demand. In its Phase 1/2 stage, it is still precommercial, but it is the clearest near-term value driver in the pipeline.
EDIT-101 LCA10 Phase 1/2
EDIT-101 is a first-in-human CRISPR eye asset for LCA10, a severe inherited childhood blindness area with strong orphan-drug pricing power. LCA affects about 1 in 33,000 to 80,000 newborns, and CEP290-related LCA10 is a rare subset, so even modest efficacy could support meaningful value.
If durability and safety hold, this can still be a high-upside Stars-style bet for Editas Medicine, Inc.; if not, the program stays a long-shot.
EDIT-102 USH2A and ADRP
EDIT-102 USH2A and ADRP is Editas Medicine, Inc.'s second retinal franchise, aimed at Usher syndrome type 2A and autosomal dominant retinitis pigmentosa. Usher 2 affects about 3 to 6 per 100,000 people, while retinitis pigmentosa hits roughly 1 in 3,500 to 4,000; both are progressive and have few approved treatments. If EDIT-102 works, it could become a core precision-ophthalmology asset.
In-house CRISPR editing platform
Editas Medicine, Inc. built an in-house CRISPR editing stack that can support more than one program from the same technical base, so it has real platform leverage. In BCG terms, this looks like a Star only if that breadth keeps turning into clinical data; right now it is still a growth engine, not a mature cash generator. Editas remains pre-commercial, so the platform’s value depends on converting science into human proof.
- One CRISPR base, multiple shots
- Strong strategic breadth
- Clinical wins still the test
Partner-backed eye therapy franchise
Editas Medicine, Inc.'s eye program stays a Star-like lane because the former Allergan partnership helped spread development cost and kept the retinal franchise alive. That matters in a field where gene-editing trials can run into nine-figure spend, so outside capital and know-how can extend runway. The ocular platform remains one of Editas Medicine, Inc.'s clearest growth options.
- Shared risk, lower cash burn
- Retina remains a core growth lane
- Partnering keeps options open
EDITAS’ High-Upside Star Assets: EDIT-301 Leads the Way
EDIT-301 is Editas Medicine, Inc.'s clearest Star-like asset: Phase 1/2 in sickle cell disease and transfusion-dependent beta-thalassemia, two large rare markets with strong demand. It can matter fast if early data stay clean.
EDIT-101 and EDIT-102 keep the ocular franchise in the Star lane too, with LCA10 at about 1 in 33,000 to 80,000 births and Usher 2 at about 3 to 6 per 100,000 people. Both are small, high-value orphan settings.
These are not cash cows yet; they are high-upside programs that need clinical proof.
| Asset | Star case | Key data |
|---|---|---|
| EDIT-301 | Lead growth driver | Phase 1/2; SCD, TDT |
| EDIT-101 | Orphan upside | LCA10; 1 in 33,000 to 80,000 |
| EDIT-102 | Second ocular shot | Usher 2; 3 to 6 per 100,000 |
What is included in the product
Detailed Word Document
Editas Medicine BCG Matrix maps its pipeline into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
Clean BCG Matrix for Editas Medicine, Inc. that quickly shows each product's quadrant and strategic priority
Reference Sources
Provides a credible source trail for Editas Medicine, helping users verify key claims fast and make better decisions.
Cash Cows
No approved products
Editas Medicine, Inc. remains a clinical-stage biotech, so as of end-2025 it had no approved therapy and no steady product cash flow. That means there are no true BCG cash cows in the portfolio. Instead, value still depends on pipeline progress, while 2025 revenue stayed non-product based.
No commercial product revenue
Editas Medicine, Inc. has no commercial product revenue because it still has 0 approved products, so it has not built a sales base or recurring end-market demand. Cash generation stays tied to financing and partnerships, which is why the company reported no product sales and must fund operations from its balance sheet and collaboration income.
No mature royalty stream
Editas Medicine has no disclosed mature royalty stream, so it does not have the steady, high-margin cash-cow engine that many biotech peers use to fund operations. Its cash profile still depends on pipeline execution and financing, not recurring royalty income.
That makes the base case more binary: if clinical programs advance, funding risk eases; if they slip, dilution risk stays high. In its latest filings, Editas still reported no blockbuster royalty franchise.
Juno collaboration economics
The Juno Therapeutics collaboration is an external cash source for Editas Medicine, not a true cash cow. The deal was reported with a $50 million upfront payment and up to $225 million in milestones, so it can fund research and soften burn, but the cash is episodic, not recurring.
- Milestones can add non-dilutive cash.
- Research support helps offset R&D burn.
- It is not a mature product revenue stream.
Allergan and AskBio alliances
Allergan and AskBio give Editas Medicine, Inc. partnership support, but they are not real BCG cash cows. In FY2025, Editas still looked like an R&D-heavy company, so these alliances matter more as cost-sharing and research bridges than as steady, low-growth cash generators.
The eye and neurology work can reduce internal R&D pressure by shifting some development risk and funding load to partners. That fits a portfolio defense role, but it does not yet look like a mature cash engine.
- Partnered R&D, not core profit
- Lowers internal funding strain
- More bridge than cash cow
Editas Has No Cash Cow—Just One-Off Collaboration Cash
Editas Medicine, Inc. had no true Cash Cows in FY2025: it still had 0 approved products, no product sales, and no recurring royalty stream. Its cash support came from collaboration income and financing, not from a mature market franchise.
The Juno Therapeutics deal is the clearest non-dilutive source, with a $50 million upfront payment and up to $225 million in milestones, but that is episodic, not steady cash flow.
| Cash Cow test | FY2025 data |
|---|---|
| Approved products | 0 |
| Product revenue | $0 |
| Juno upfront | $50 million |
| Juno milestones | Up to $225 million |
Preview Before You Purchase
Editas Medicine, Inc. Reference Sources
You’re previewing the exact Editas Medicine, Inc. BCG Matrix document you’ll receive after purchase. There are no placeholders, watermarks, or demo sections—just the final, fully formatted file. Once purchased, it’s ready for immediate download, use, or presentation. What you see here is exactly what you get.
Dogs
Early neurology discovery program
Editas Medicine’s early neurology discovery program is undisclosed, preclinical, and still has no visible commercial footprint. With no reported program revenue and high technical risk, it fits BCG’s "question mark" profile, not a star. If data stay thin, it can keep burning cash without adding near-term scale or growth.
Solid-tumor NK cell therapy
Editas Medicine, Inc.’s gene-edited NK cell work sits in a crowded oncology field, where most rivals are also chasing solid tumors. Solid tumors make up about 90% of adult cancers, but cell therapy still struggles with tumor entry, persistence, and immune escape. With no clear market position yet and high R&D burn, this looks like a Question Mark in the BCG Matrix.
Alpha-beta T cell therapy
Editas Medicine's alpha-beta T cell therapy is a Dog: it is still precommercial, with no sales to offset spend. Cell therapy rivals like autologous and allogeneic programs keep pressure high, while manufacturing scale and durability still limit adoption. If it fails to show clear differentiation in 2025-2026, it risks becoming a low-return cash sink.
Gamma delta T cell therapy
Editas Medicine's gamma delta T cell therapy is still early and exploratory, so it fits a weak BCG spot: low market share, high uncertainty, and no clear commercial proof yet. The science may be interesting, but without strong human data, repeatable efficacy, or a clear path to revenue, it stays a question mark rather than a star.
- Early-stage, exploratory science
- Limited commercial proof
- Weak BCG position today
- Needs strong data to improve
Non-core exploratory oncology assets
Editas Medicine, Inc. keeps these oncology programs in the dog bucket because they sit outside the company’s core retina and blood-disease focus, have no product sales, and offer little near-term cash return. In 2025, the company still had no marketed oncology asset, so these efforts stayed optional, not core.
No oncology sales or approved products.
Low visibility versus core pipeline.
Likely pruning target if cash tightens.
Editas oncology stays a Dog: no sales, high burn, little traction
Editas Medicine, Inc.’s oncology assets still look like Dogs: no approved product, no 2025 sales, and no clear share in a crowded cell-therapy market. With limited proof and high R&D spend, these programs keep draining cash instead of adding scale. Unless 2026 data show a sharp jump in efficacy or partnering, they stay low-return bets.
| Program | BCG | Signal |
|---|---|---|
| Oncology pipeline | Dog | No sales, low share |
Question Marks
EDIT-101 LCA10
EDIT-101 LCA10 is a question mark in Editas Medicine, Inc.’s BCG Matrix because it targets the rare Leber congenital amaurosis 10 retinal market and has no commercial share yet. Its upside depends on clinical and FDA success; in the latest disclosed update, Editas still had no product sales and R&D remained its main cash use. If the data mature well, it could move toward star status.
EDIT-102 retinal degeneration
EDIT-102 for USH2A and ADRP sits in a fast-growing precision-medicine niche, but it is still in Phase 1/2, so real-world uptake is not proven yet. The target disease burden is meaningful: inherited retinal disease affects about 1 in 3,000 people, but treatment options remain limited. That early, high-upside, high-risk profile makes it a classic question mark.
EDIT-301 hemoglobinopathies
EDIT-301 targets sickle cell disease and beta-thalassemia, two serious blood disorders with large unmet need, but it is still unproven commercially. Gene-editing rivals from Vertex, CRISPR Therapeutics, and bluebird bio have already raised the bar, while Editas Medicine keeps spending heavily on R&D and trials. That makes the program a classic question mark: high potential, high cash burn, and no clear market share yet.
Oncology cell therapy platforms
Editas Medicine, Inc.’s NK, alpha-beta T cell, and gamma delta T cell platforms fit a Question Mark: they target fast-growing oncology cell therapy markets, but they are still precommercial and have no meaningful market share.
The key issue is proof, not potential. These programs need strong clinical data and clear efficacy signals to justify more capital, especially while Editas Medicine, Inc. remains in a cash-burning development phase.
- Fast market, zero share.
- Precommercial, high execution risk.
- Major data wins needed.
Discovery-stage pipeline expansion
Editas Medicine, Inc. keeps expanding its discovery-stage genome-editing pipeline, but this is still a Question Mark in BCG terms: high optionality, low near-term cash return, and a real chance of failure. In FY2025, the Company still had no approved product, so these early bets are more about future platform value than current earnings.
- High upside, but no near-term revenue
- Preclinical bets can fail fast
- Pipeline breadth supports future option value
- Needs proof before capital scales up
Editas’ Early Bets: High Upside, No Sales Yet
Editas Medicine, Inc.’s Question Marks are early-stage bets with no commercial share yet. EDIT-101, EDIT-102, EDIT-301, and the cell-therapy platforms all have high upside, but they still need clinical proof, FDA wins, and a path to revenue. The latest disclosed update still showed no product sales and heavy R&D spend.
| Program | Status | BCG signal |
|---|---|---|
| EDIT-101 | Rare eye disease, no sales | High upside, high risk |
| EDIT-102 | Phase 1/2 | Unproven demand |
| EDIT-301 | Precommercial | Needs data win |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.